Update – 16/06/2021
June 16, 2021
Who we are
Action Digital is a full-service digital agency based in Cyprus offering services in web
As of the latest update by the Greek authorities, the total number of confirmed Covid-19 diagnosed cases in Greece is 416,195. 22 new deaths were reported raising the total number to 12,465. The number of patients treated in intensive care units is currently 343. 835 new cases were announced yesterday in Greece. 397 of the new cases were found in the Attica region and 68 new cases in the Thessaloniki region.
Greece’s Civil Aviation Authority on Tuesday issued its updated guidelines for travel into the country during the ongoing coronavirus pandemic.
Under the latest rules, travel into Greece without the need to quarantine on arrival is permitted only from the European Union and the Schengen area; however, the following are exempted from the ban on arrivals from third countries: Australia, Bahrain, Belarus, Bosnia-Herzegovina, Canada, China, Israel, Kuwait, Montenegro, New Zealand, North Macedonia, Qatar, Russia, Rwanda, Saudi Arabia, Serbia, Singapore, South Korea, Thailand, Ukraine, the United Arab Emirates, United Kingdom and United States of America.
All travelers coming into Greece must submit a passenger locator form (PLF) and have one of the three following documents: an official vaccination certificate, stating that 14 days have passed since full vaccination for Covid-19; a negative PCR test (in Greek, English, French, German, Italian, Spanish or Russian) performed less than 72 hours before arrival; or a recovery certificate (in Greek, English, French, German, Italian, Spanish or Russian) stating that the person in question has recovered from the coronavirus in the past nine months.
A new coronavirus vaccine called Novavax, from a company by the same name, has proven to be 90% effective in trials, according to its maker.
The new vaccine candidate appears on the horizon just as inoculations have slowed in the United States, where more than 44% of citizens are now fully vaccinated, but when other regions of the world variants of concern are posing an ever greater problem.
The latest study undertaken by the Novavax firm, headquartered in Gaithersburg, Maryland, trialed the candidate in the United States as well as Mexico. Earlier studies had been undertaken in Great Britain and in South Africa.
The two-inoculation vaccine proved to be approximately 90% effective overall, and according to the company, the preliminary data so far shows that the shot is safe. The effectiveness figures coming out of the study are parallel to those demonstrated by both the Pfizer/BioNTech and Moderna vaccines in their studies.
The Novavax vaccine, unlike the Pfizer/BioNTech shot which hit the market first, is very easy to transport and store, offering increased hope to far-flung nations which will be the target for a great many of the doses manufactured as soon as their emergency use is authorized. It can be stored for some time at normal refrigerator temperatures.
If and when it is approved for emergency use, the Novavax inoculation will be the fifth coronavirus vaccine to be produced in the fight against Covid-19 in the West after the Pfizer/BioNTech, Moderna, Johnson & Johnson and AstraZeneca shots.
In more detail, the 835 new cases detected per Regional Unit:
